<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002339</url>
  </required_header>
  <id_info>
    <org_study_id>120</org_study_id>
    <secondary_id>R-0220</secondary_id>
    <nct_id>NCT00002339</nct_id>
  </id_info>
  <brief_title>A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems</brief_title>
  <official_title>An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the safety, toleration, and efficacy of fluconazole oral suspension in the
      treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8 weeks.
      Patients are evaluated weekly, and treatment continues for 2 weeks after resolution of
      symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end of
      treatment. Patients undergo follow-up at 2 weeks post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Candidiasis, Esophageal</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  AIDS or other immunocompromising condition.

          -  Candidal esophagitis.

          -  Life expectancy of at least 2 months.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Evidence of non-candidal systemic fungal infection.

          -  Abnormalities that may preclude esophagoscopy or endoscopy.

          -  Unable to tolerate fluconazole.

          -  Unable to give informed consent.

          -  Enrollment in other experimental trials of approved or non-approved drugs or systemic
             compounds (unless approved by the Pfizer Clinical Monitor).

          -  Other condition that would make patient unsuitable for enrollment.

        Concurrent Medication:

        Excluded:

          -  Concomitant oral or topical antifungal agent.

          -  Other experimental medications.

        Patients with the following prior condition are excluded:

        History of allergy to imidazoles or azoles.

        Prior Medication:

        Excluded:

          -  Any oral or topical antifungal therapy within the past 3 days. Active use of illicit
             or illegal drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Veterans Administration Med Ctr</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Agresti MG, de Bernardis F, Mondello F, Bellocco R, Carosi GP, Caputo RM, Milazzo F, Chiodo F, Giannini V, Minoli L, et al. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. Eur J Epidemiol. 1994 Feb;10(1):17-22.</citation>
    <PMID>7957784</PMID>
  </reference>
  <verification_date>April 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Esophagitis</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Candidiasis</keyword>
  <keyword>Immunocompromised Host</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

